Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid - Two case reports and literature review

MedGenMed Medscape General Medicine

Volumn 8, Issue 4, 2006, Pages

  Iannello, Silvia ^a   Milazzo, Paolina ^a   Bordonaro, Fabio ^a   Belfiore, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CASE REPORT; COLON ADENOCARCINOMA; COLON RESECTION; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; HYPERTROPHIC SCAR; KELOID; LOW DRUG DOSE; MALE; VASCULARIZATION; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; WOUND HEALING;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CICATRIX, HYPERTROPHIC; ENALAPRIL; FEMALE; HUMANS; KELOID; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; WOUND HEALING;

EID: 33846306369     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Nemeth AJ. Keloids and hypertrophic scars. J Dermatol Surg Oncol. 1993;19:738-746. Abstract
2. Bardot J. Cutaneous cicatrix: Natural course, anomalies and prevention [French]. Rev Pract. 1994;44:1763-1768.
3. Burd A, Huang L. Hypertrophic response and keloid diathesis: Two very different forms of scar. Plast Reconstr Surg. 2005:150e-157e.
4. Gira AK, Brown LF, Washington CV, Cohen C, Arbiser JL. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol. 2004;50:850-853. Abstract
5. Thomas DW, Hopkinson I, Harding KG, Shepherd JP. The pathogenesis of hypertrophic/keloid scarring. Int J Oral Maxillofac Surg. 1994;23:232-236. Abstract
6. Alster TS, West TB. Treatment of scars: a review. Ann Plast Surg. 1997;39:418-432. [Comments in: Ann Plast Surg. 1998;41:685 and 685-686.]
7. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999;104:1435-1458. Abstract
8. Mustoe TA. Scars and keloids. BMJ. 2004;328:1329-1330. Abstract
9. Berman B, Flores F. The treatment of hypertrophic scars and keloids. Eur J Dermatol. 1998;8:591-595. Abstract
10. Beausang E, Floyd H, Dunn KW, Orton CI, Ferguson MW. A new quantitative scale for clinical scar assessment. Plast Reconstr Surg. 1998;102:1954-1961. Abstract
11. Tredget EE, Nedelec B, Scoff PG, Ghahary A. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am. 1997;77:701-730. Abstract
12. Botwood N, Lewanski C, Lowdell C. The risks of treating keloids with radiotherapy. Br J Radiol. 1999;72:1222-1224. Abstract
13. Driscoll B. Treating keloids with carbon dioxide lasers. Arch Otolaryngol Head Neck Surg. 2001;127:1145.
14. Uppal RS, Khan U, Kakar S, Talas G, Chapman P, McGrouther AD. The effects of a single dose of 5-fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision. Plast Reconstr Surg. 2001;108:1218-1224. Abstract
15. Mustoe TA, Cooter RD, Gold MH, et al; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560-571. Abstract
16. Poochareon VN, Berman B. New therapies for the management of keloids. J Craniofac Surg. 2003;14:654-657. Abstract
17. Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: Retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg. 2003;111:547-553; discussion 554-555.
18. Ragoowansi R, Cornes PG, Moss AL, Glees JP. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast Reconstr Surg. 2003;111:1853-1859. Abstract
19. Wong MS. Intralesional excision of keloids. Plast Reconstr Surg. 2005:116:675.
20. Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006;117:286-300. Abstract
21. Davison SP, Mess S, Kauffman LC, Al-Attar A. Ineffective treatment of keloids with interferon alpha-2b. Plast Reconstr Surg. 2006;117:247-252. Abstract
22. Uysal AC. Topical interferon-alpha-2b and keloid treatment: a place for pretreatment? Plast Reconstr Surg. 2006;117:1645-1646.
23. Amadeu TP, Braune AS, Porto LC, Desmouliere A, Costa AM. Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. Wound Repair Regen. 2004;12:169-174. Abstract
24. Phan TT, Lim IJ, Bay BH, et al. Differences in collagen production between normal and keloid-derived fibroblasts in serum-media co-culture with keloid-derived keratinocytes. J Dermatol Sci. 2002;29:26-34. Abstract
25. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg. 1999;43:179-184. Abstract
26. Liu W, Wang DR, Cao YL. TGF-beta: A fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. Curr Gene Ther. 2004;4:123-136. Abstract
27. Colwell AS, Phan TT, Kong W, Longaker MT, Lorenz PH. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast Reconstr Surg. 2005;116:1387-1390; discussion 1391-1392.
28. Bayat A, Bock O, Mrowietz U, Ollier WE, Ferguson MW. Genetic susceptibility of keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels. Plast Reconstr Surg. 2003;111:535-543; discussion 544-546.
29. Beer TW, Baldwin HC, Goddard JR, Gallagher PJ, Wright DH. Angiogenesis in pathological and surgical scars. Hum Pathol. 1998;29:1273-1278. Abstract
30. Ueda K, Furuya E, Yasuda Y, Oba S, Tajima S. Keloids have continuous high metabolic activity. Plast Reconstr Surg. 1999;104:694-698. Abstract
31. Katzung BG. Basic & Clinic Pharmacology, 5th ed. East Norwalk, Conn: Prentice-Hall International Inc. (Appleton & Lange); 1996: 156-157 and 253-254.
32. Sun Y, Ratajaska A, Zhou G, Weber KT. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395-403. Abstract
33. Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286:L156-164. Abstract
34. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol. 1992;19:713-721. [Comment in: J Am Coll Cardiol. 1992;19:722-723.]
35. White HD. Remodelling of the heart after myocardial infarction. Aust N Z J Med. 1992;22(5 Suppl):601-606.
36. Jugduft BI, Khan MI, Jugdutt SJ, Blinston GE. Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. Circulation. 1995;91:802-812. Abstract
37. Pelouch V, Kolar F, Ost'adal B, Milerova M, Cihak R, Widimsky J. Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: Effect of enalapril. Cardiovasc Drugs Ther. 1997;11:177-185. Abstract
38. Jugdutt BI, Musat-Marcu S. Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction. Can J Cardiol. 2000;16:617-625. Abstract
39. Dean RG, Balding LC, Candido R, et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem. 2005;53:1245-1256. Abstract
40. Ward WF, Molteni A, Ts'ao C, Hinz JM. The effect of captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol. 1990;63:349-354. Abstract
41. Nguyen L, Ward WF, Ts'ao CH, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: A potential antifibrotic mechanism. Proc Soc Exp Biol Med. 1994;205:80-84. Abstract
42. Volders PG, Daemen MJ. Interstitial fibrosis and angiotensin-converting enzyme inhibition in patients with end-stage myocardial infarction. J Am Coll Cardiol. 1998;32:552-553. [Comment in: J Am Coll Cardiol. 1997;30:76-82.]
43. Uhal BD, Gidea C, Bargout R, et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol. 1998;275:L1013-1017. Abstract
44. Molteni A, Moulder JE, Cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol. 2000;76:523-532. Abstract
45. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46:250-256. Abstract
46. Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol. 1997;29:1375-1386. Abstract
47. Sun Y, Ramires FJ, Zhou G, Ganjam VK, Weber KT. Fibrous tissue and angiotensin II. J Mol Cell Cardiol. 1997;29:2001-2012. Abstract
48. Wang B, Ansari R, Sun Y, Postlethwaite AE, Weber KT, Kiani MF. The scar neovasculature after myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 2005;289:H108-113. Abstract